Literature DB >> 36253441

The role of exercise in the treatment of depression: biological underpinnings and clinical outcomes.

Ryan E Ross1,2, Catherine J VanDerwerker3, Michael E Saladin3,4, Chris M Gregory5,3.   

Abstract

Globally, depression is a leading cause of disability and has remained so for decades. Antidepressant medications have suboptimal outcomes and are too frequently associated with side effects, highlighting the need for alternative treatment options. Although primarily known for its robust physical health benefits, exercise is increasingly recognized for its mental health and antidepressant benefits. Empirical evidence indicates that exercise is effective in treating individuals with depression; however, the mechanisms by which exercise exerts anti-depressant effects are not fully understood. Acute bouts of exercise have been shown to transiently modulate circulating levels of serotonin and norepinephrine, brain-derived neurotrophic factor, and a variety of immuno-inflammatory mechanisms in clinical cohorts with depression. However, exercise training has not been demonstrated to consistently modulate such mechanisms, and evidence linking these putative mechanisms and reductions in depression is lacking. The complexity of the biological underpinnings of depression coupled with the intricate molecular cascade induced by exercise are significant obstacles in the attempt to disentangle exercise's effects on depression. Notwithstanding our limited understanding of these effects, clinical evidence uniformly argues for the use of exercise to treat depression. Regrettably, exercise remains underutilized despite being an accessible, low-cost alternative/adjunctive intervention that can simultaneously reduce depression and improve overall health. To address the gaps in our understanding of the clinical and molecular effects of exercise on depression, we propose a model that leverages systems biology and multidisciplinary team science with a large-scale public health investment. Until the science matches the scale of complexity and burden posed by depression, our ability to advance knowledge and treatment will continue to be plagued by fragmented, irreproducible mechanistic findings and no guidelines for standards of care.
© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Entities:  

Year:  2022        PMID: 36253441     DOI: 10.1038/s41380-022-01819-w

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   13.437


  170 in total

1.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

2.  American College of Sports Medicine position stand. Exercise and physical activity for older adults.

Authors:  Wojtek J Chodzko-Zajko; David N Proctor; Maria A Fiatarone Singh; Christopher T Minson; Claudio R Nigg; George J Salem; James S Skinner
Journal:  Med Sci Sports Exerc       Date:  2009-07       Impact factor: 5.411

3.  Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance.

Authors:  Howard G Birnbaum; Ronald C Kessler; David Kelley; Rym Ben-Hamadi; Vijay N Joish; Paul E Greenberg
Journal:  Depress Anxiety       Date:  2010       Impact factor: 6.505

4.  Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research.

Authors:  C J Caspersen; K E Powell; G M Christenson
Journal:  Public Health Rep       Date:  1985 Mar-Apr       Impact factor: 2.792

5.  What are the most common conditions in primary care? Systematic review.

Authors:  Caitlin R Finley; Derek S Chan; Scott Garrison; Christina Korownyk; Michael R Kolber; Sandra Campbell; Dean T Eurich; Adrienne J Lindblad; Ben Vandermeer; G Michael Allan
Journal:  Can Fam Physician       Date:  2018-11       Impact factor: 3.275

6.  Excess mortality in depression: a meta-analysis of community studies.

Authors:  Pim Cuijpers; Filip Smit
Journal:  J Affect Disord       Date:  2002-12       Impact factor: 4.839

7.  Depression and multimorbidity: a cross-sectional study of 1,751,841 patients in primary care.

Authors:  Daniel J Smith; Helen Court; Gary McLean; Daniel Martin; Julie Langan Martin; Bruce Guthrie; Jane Gunn; Stewart W Mercer
Journal:  J Clin Psychiatry       Date:  2014-11       Impact factor: 4.384

8.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Jonathan W Stewart; Andrew A Nierenberg; Michael E Thase; Louise Ritz; Melanie M Biggs; Diane Warden; James F Luther; Kathy Shores-Wilson; George Niederehe; Maurizio Fava
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

9.  Association of Symptoms of Depression With Cardiovascular Disease and Mortality in Low-, Middle-, and High-Income Countries.

Authors:  Selina Rajan; Martin McKee; Sumathy Rangarajan; Shrikant Bangdiwala; Annika Rosengren; Rajeev Gupta; Vellappillil Raman Kutty; Andreas Wielgosz; Scott Lear; Khalid F AlHabib; Homer U Co; Patricio Lopez-Jaramillo; Alvaro Avezum; Pamela Seron; Aytekin Oguz; Iolanthé M Kruger; Rafael Diaz; Mat-Nasir Nafiza; Jephat Chifamba; Karen Yeates; Roya Kelishadi; Wadeia Mohammed Sharief; Andrzej Szuba; Rasha Khatib; Omar Rahman; Romaina Iqbal; Hu Bo; Zhu Yibing; Li Wei; Salim Yusuf
Journal:  JAMA Psychiatry       Date:  2020-10-01       Impact factor: 21.596

10.  Population-based cohort analyses of the bidirectional relationship between type 2 diabetes and depression.

Authors:  Pei-Chun Chen; Yen-Ting Chan; Hua-Fen Chen; Ming-Chung Ko; Chung-Yi Li
Journal:  Diabetes Care       Date:  2012-11-12       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.